We are live on ! Find out more
BLRX

BioLineRX
BLRX

19 hedge funds and large institutions have $17.9M invested in BioLineRX in 2014 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

124% more capital invested

Capital invested by funds: $8.01M → $17.9M (+$9.92M)

58% more funds holding

Funds holding: 12 → 19 (+7)

Holders
19
Holders Change
+7
Holders Change %
+58.33%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
5
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$5.21M
2
SM
Senvest Management
New York
+$2.25M
3
BI
BVF Inc
California
+$2.19M
4
OM
Opaleye Management
Massachusetts
+$2.02M
5
SFM
Sphera Funds Management
Israel
+$1.64M

Top Sellers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
-$85K
2
ARTA
A.R.T. Advisors
New York
-$28K
3
TRCT
Tower Research Capital (TRC)
New York
-$28K

BLRX Hedge Fund Activity: Q1 2014 in Review

19 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2014, worth a combined $17.9M — up 124% from $8.01M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new BLRX positions and 3 closed out — a net gain of 7 holders — while 5 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $5.21M. The largest seller was UBS AM, exiting entirely with an estimated $85K sold.

  • 19 institutional investors held BioLineRX (BLRX) as of Q1 2014, up from 12 in Q4 2013.
  • Funds reported $17.9M of BioLineRX stock for Q1 2014, up 124% quarter-over-quarter.
  • 10 funds opened new BioLineRX positions in Q1 2014 and 3 closed out, a net change of +7 holders.
  • The largest BioLineRX buyer in Q1 2014 was Sabby Management, an estimated $5.21M added.
  • The largest BioLineRX seller in Q1 2014 was UBS AM, an estimated $85K sold.

Based on aggregated 13F filings for Q1 2014.